Horst Rose
Direktor/Vorstandsmitglied bei ImVision Therapeutics, Inc.
Profil
Horst Rose is currently a Director at ImVision Therapeutics, Inc. He was previously the Chief Executive Officer at Elégance GmbH, Director-Operations at ImVisioN GmbH, Physiology Professor at RWTH Aachen University, Head-Medical Research at Biovision AG, and Chief Operating & Human Resources Officer at ImVisioN Therapeutics AG.
He was also the Head-Research & Development at Abbott Products GmbH.
Dr. Rose received his undergraduate and doctorate degrees from RWTH Aachen University.
Aktive Positionen von Horst Rose
Unternehmen | Position | Beginn |
---|---|---|
ImVision Therapeutics, Inc.
ImVision Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImVision Therapeutics, Inc. develops proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. The company was founded on January 28, 2005 and is headquartered in Hanover, Germany. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Horst Rose
Unternehmen | Position | Ende |
---|---|---|
ImVisioN Therapeutics AG
ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | Geschäftsführer | 13.02.2014 |
Biovision AG | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2005 |
Abbott Products GmbH | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2002 |
RWTH Aachen University | Corporate Officer/Principal | - |
Elégance GmbH
Elégance GmbH Catalog/Specialty DistributionRetail Trade Elégance GmbH provides mail-order services. The company was founded in 1938 and is headquartered in Aachen, Germany. | Vorstandsvorsitzender | - |
Ausbildung von Horst Rose
RWTH Aachen University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
ImVision Therapeutics, Inc.
ImVision Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImVision Therapeutics, Inc. develops proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. The company was founded on January 28, 2005 and is headquartered in Hanover, Germany. | Health Technology |
ImVisioN GmbH
ImVisioN GmbH Miscellaneous Commercial ServicesCommercial Services ImVisioN GmbH provides research in intralymphatic immunotherapy. It is a biotechnology company which specializes the use of intralymphatic immunotherapy to develop treatments for major allergies. Its product, IVN201, is a MAT immunotherapeutic that targets cat dander allergy, a common allergy inadequately addressed by available therapeutic interventions. The company was founded in 2005 and is headquartered in Hanover, Germany. | Commercial Services |
Biovision AG | |
ImVisioN Therapeutics AG
ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | Commercial Services |
Abbott Products GmbH | |
Elégance GmbH
Elégance GmbH Catalog/Specialty DistributionRetail Trade Elégance GmbH provides mail-order services. The company was founded in 1938 and is headquartered in Aachen, Germany. | Retail Trade |